www.ribabooks.com/design-studio-vol-2-intelligent-control-2021-disruptive-technologies-2021_9781859469705.

These can broadly be clustered as follows:.The perceived immaturity of the state-of-the-art.

There is a belief that the technology involved in intensified chemistry is not very mature and therefore carries substantial risk.Some of the small-scale hardware has not been fully industrialised, the developing data collection, process and quality control approaches have not been fully tested with regulatory authorities..Complicated supply chain.

Pharmaceutical manufacturing of a single product through its lifecycle spans multiple functions and sites within each organisation and spans multiple organisations through product acquisitions and contract manufacturing.Thus, the breadth of what needs to be changed to deploy a new platform technology is significant.. Resistance to challenging accepted practice.

Regulatory and patient safety risks are always high up the agenda for the pharmaceutical industry.

The unfamiliar and the new are assessed as having higher risk than the known.. How manufacturing sits versus perceived value creation in the pharmaceutical companies.In fact, a range of complementary elements have already been developed and delivered on The Forge..

Developing the façade solution around the structural platform at an early stage, allowed us to really optimise the use of materials and detailing and create the most efficient units for handling in the factory and on-site.. Wojciech Brozyna, Managing Director, Alupro.Accuracy in installation is achieved via factory conditions on site:.

Standardised platforms and components.Increased use of standardised, repeatable, design and components inherently lead to less variance and more standardised tasks on site, which already reduces the risk of the need for changes and thus the potential to deviate from the original design..